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Abstract 
Background Questions remain regarding preterm delivery (PTD) risk in HIV-infected 
women on antiretroviral therapy (ART), including the role of ritonavir-boosted protease 
inhibitors (PI/r), timing of ART initiation and immune status. 
Methods We examined data from the UK/Ireland National Study of HIV in Pregnancy 
and Childhood on women with HIV delivering a singleton live infant in 2007-2015, 
including those pregnancies receiving PI/r-based (n=4184) or non-nucleoside reverse 
transcriptase inhibitors (NNRTI)-based regimens (n=1889). 
We conducted logistic regression analysis adjusted for risk factors associated with PTD 
and stratified by ART at conception and CD4 count to minimise bias by indication for 
treatment and to assess whether PTD risk differs by ART class and specific drug 
combinations. 
Results Among women conceiving on ART, lopinavir/ritonavir was associated with 
increased PTD risk in those with CD4 ≤350 (aOR 1.99[1.02, 3.85]) and with CD4>350 
(aOR 1.61[1.07, 2.43]) versus women on NNRTI-based (mainly efavirenz and 
nevirapine) regimens in the same CD4 sub-group. Associations between other PI-based 
regimens (mainly atazanavir and darunavir) and PTD risk were complex. Overall, PTD 
risk was higher in women who conceived on ART, had low CD4 count and were older. 
No trend of association of PTD with tenofovir or any specific drug combinations were 
observed. 
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Conclusions Our data support a link between the initiation of ritonavir-boosted/lopinavir-
based ART pre-conception and PTD in subsequent pregnancies, with implications for 
treatment guidelines. Continued monitoring of PTD risk is needed as increasing numbers 
of pregnancies are conceived on new drugs. 
Keywords: drug combination; gestational age; HIV infections; lopinavir; premature 
birth; protease inhibitors 
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Introduction 
It is now widely accepted that antiretroviral therapy (ART) in pregnancy is associated 
with increased risk of preterm delivery (PTD), but questions remain about the exact 
nature of this association, for example the roles of timing of ART initiation (pre- or post-
conception) and maternal immunological status (e.g. CD4 count) and the extent to which 
specific drugs or regimens are involved in this association [1-4]. Pregnant women on 
protease inhibitor (PI) regimens may be at higher risk of PTD [5-8]. Limited data on 
mechanisms suggest that PIs may reduce progesterone levels in pregnancy [9], leading to 
fetal growth restriction. Progesterone may also play an important role in PTD [10, 11]. 
Certain antiretroviral drugs (ARV), namely ritonavir (RTV), widely used as a booster for 
other PI and the nucleoside “backbone” tenofovir (TDF)/emtricitabine (FTC) may also 
interact with PIs and increase PTD risk [12, 13]. Most recently, assessment of individual 
ART regimens has been recommended to better understand the differences and causes of 
adverse perinatal outcomes between ART [14, 15]. 
In a previous analysis of data from the UK and Ireland National Study of HIV in 
Pregnancy and Childhood (NSHPC) based on pregnancies delivered between 1990 and 
2005 [6] we showed an increased rate of PTD in women on combination ART (cART) 
(14%) versus mono/dual therapy (10%). Since then, new antiretroviral drugs have been 
licensed and the drug combinations used routinely during pregnancy have changed 
substantially, with mono/dual therapy no longer used. Additionally, an increasing 
proportion of women are conceiving on ART [16]. 
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In this paper we examine whether pregnant women on a regimen that includes a PI 
boosted with RTV (PI/r) are at higher risk of delivering preterm compared with pregnant 
women on an NNRTI-based regimen and whether this risk varies by ART use at 
conception, CD4 count (high vs low) and ART drug combination. 
Methods 
Study population 
The NSHPC is a national surveillance study that collects comprehensive population-
based data on all HIV-positive pregnant women and their children seen for care in the 
UK and Ireland. Information on pregnancy and delivery is collected from obstetric 
respondents in all maternity units, and HIV-exposed infants are followed up through their 
paediatrician to establish infection status. Full methodological details have been 
described elsewhere [17, 18]. The NSHPC has received ethical approval from the London 
Multi-Centre Research Ethics Committee (MREC/04/2/009). 
Inclusion criteria 
We included pregnancies with known gestational age resulting in a singleton live birth 
delivered between 2007 and 2015, in women diagnosed with HIV before delivery and 
reported to the NSHPC by March 2016. To investigate the association of PTD with ART 
class we compared pregnancies exposed to a PI/r-based regimen with those exposed to 
an NNRTI-based regimen and distinguished RTV-boosted lopinavir (LPV/r), the 
predominant PI in our study, from other PI to avoid results being driven by LPV/r. We 
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defined a PI/r-based regimen as a regimen that included a PI, RTV booster and two 
nucleoside reverse transcriptase inhibitors (NRTI) drugs (the “backbone”); similarly an 
NNRTI-based regimen included an NNRTI plus two NRTIs. We excluded 211 pregnancies 
with no or ‘unspecified’ data on ART, 145 with ART started <28 days before delivery and 
192 pregnancies exposed to mono/dual regimens, 90 to integrase inhibitors, 77 to 
unboosted PI and 1510 to more than one ARV drug combination during the pregnancy. 
We further excluded 1371 earlier pregnancies in women with repeated pregnancies, 
keeping only the most recent one. 
Definitions 
Gestational age at delivery, in completed gestational weeks, was reported by the 
respondent based on expected date of delivery. We defined PTD as a delivery at <37 
weeks, moderate PTD (MPTD) as delivery at 34-36 weeks and very PTD (VPTD) as 
delivery at <34 weeks [13]. Small for gestational age (SGA) was defined according to 
United States sex-specific standards [19]. Baseline CD4 cell count was defined as the 
first CD4 count reported in pregnancy. We grouped maternal country of origin into six 
main world regions according to UN classification; Western European and Western 
Countries+ Eastern Europe (WEWC+EE), Eastern Africa, Middle/Southern Africa, 
Western Africa, Caribbean (CRB) and Other. 
Statistical analysis 
First, we examined the overall associations of PTD with LPV/r-, other PI/r- and NNRTI-
based regimens using logistic regression and multinomial logistic regression to 
investigate whether this association varied by MPTD and VPTD. To minimise bias by 
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indication for treatment we further excluded pregnancies in women with a history of 
injecting drug use (IDU) and those with no data on CD4 and conducted stratified analyses 
on four sub-groups of pregnancies: (1) no ART at conception and baseline CD4 ≤350 
cell/mm3; (2) no ART at conception and baseline CD4 >350 cell/mm3; (3) ART at 
conception and baseline CD4 ≤350 cell/mm3; (4) ART at conception and baseline CD4 
>350 cell/mm3. Finally, we investigated these associations by drug-specific regimen 
(rather than ART class). We included any drug combinations received in ≥5% of 
pregnancies and selected the combination with the lowest PTD rate as the baseline for 
comparison. 
Analyses were adjusted for potential confounders identified a priori based on previous 
literature [6, 12, 20]: i.e. year of delivery (continuous), maternal age at delivery (divided 
into quartiles), parity (primiparous vs multiparous), IDU history, antenatal CD4 count 
(≤350 cell/mm3, >350 cell/mm3), ART at conception and maternal country of origin. 
Results were considered statistically significant at a p-value of <0.05. Differences in 
proportions were tested for statistical significance using the chi-square test. Statistical 
analyses were performed using Stata version 13.1 (StataCorp, College Station, TX, 
USA). 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
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Results 
The final dataset included 6073 pregnancies, mainly in women from sub-Saharan Africa 
(4445/6073, 73•2%) and of median age of 33 years (IQR 29-36); 3090 (50•9%) 
pregnancies were conceived on ART while the remainder started ART on average at 19•1 
gestational weeks (15•7-22•1). Median CD4 count at baseline was 440 (IQR 311-596) 
cells/mm3 and in 3272 pregnancies (68•5%) was above 350 cells/mm3. Of these CD4 
counts, 42•4% were measured in the first, 45•3% in the second and 12•4% in the third 
trimester. CD4 count was missing in 1270 pregnancies; these pregnancies tended to be 
at the beginning of study (P=0•007) but there was no difference in PTD rate (P=0•27) or 
use of ART class (P=0•51) compared with pregnancies with available CD4 count. PI/r-
based regimens were the most common accounting for 4184 (68•9%) pregnancies, of 
which 2368 (39•0%) received LPV/r; the remaining 1889 (31•1%) pregnancies received a 
NNRTI-based (mainly efavirenz [EFV] and nevirapine [NVP]) regimen. The number of 
women receiving LPV/r in pregnancy was particularly high at the start of the study 
period but the number swiftly declined subsequently (Figure 1) due to changes in 
commissioning and adult treatment guidelines. Overall, the PTD rate was 10•4% 
(629/6073) and the VPTD rate was 3•8% (228/6073). Women receiving LPV/r had higher 
PTD rates than women receiving other PI/r- or NNRTI-based regimens (Table 1). 
Among 5711 infants with available birthweight data, 1163 (20•4%) were SGA at delivery. 
Sixteen infants (0•26% of 6073), all born full-term, were HIV-infected. Ten infants 
(0•16%), eight of whom were VPTD, one MPTD and one full-term, died within the first 28 
 Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. 
 
days. Congenital abnormalities were reported in 2•9% (171/5867) of infants. Compared 
to full term infants preterm infants were more likely to have a congenital abnormality 
(40/595 [6•7%] vs. 131/5272 [2•5%], P <0•001) and more likely to be SGA compared to 
full-term infants ([149/594] [25•1%] vs. [1014/5117] [19•8%], P =0•003). 
After adjustment for other risk factors associated with PTD, overall analysis suggested 
an association of PTD with LPV/r, low CD4 count (≤350cells/mm3), ART at conception 
and older maternal age (>36years) (Table 2). MPTD was associated with LPV/r and 
mother originating in the Caribbean VPTD and VPTD with LPV/r and IDU history (SDC 
Table 1, http://links.lww.com/QAD/B189). 
Association of preterm delivery with ART class stratified by ART at conception and CD4 
count 
The highest rate of PTD (13•7%) was observed in women on ART at conception and low 
CD4 count (≤350 cells/mm3) and the lowest PTD rate (8•8%) in those on ART at 
conception with high CD4 counts (>350 cells/mm3) (SDC Table 2a-b). Stratified analysis 
suggested that irrespective of baseline CD4, PTD risk increased in women conceiving on 
LPV/r (Figure 2) Women who conceived on other PI/r-regimens were also at higher PTD 
risk when CD4 ≤350 cells/mm3 but no clear pattern was observed when CD4 >350 
cells/mm3 (for example, PTD rates varied widely between PI/r-based regimens from 
4.9% in women who conceived on RTV-boosted atazanavir [ATV/r]+ TDF/FTC to 13•4% in 
women who conceived on RTV-boosted darunavir [DRV/r]+ TDF/FTC). 
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Where ART was initiated after conception, no significant associations between PTD and 
LPV/r- or other PI/r-based regimens were observed irrespective of CD4 count (Figure 2). 
Despite exclusion from our analyses of women starting ART <28 days before delivery, 
some women were included who initiated ART beyond defined gestational age cut-offs 
for PTD (particularly very or moderate PTD) and were therefore not exposed to ART 
during the period that they were at risk for PTD. We therefore conducted a sensitivity 
analysis excluding women starting ART at ≥28 gestational weeks (n=91) but results did 
not vary and no significant associations were observed (SDC Table 4). 
Association of preterm delivery with ART by drug combinations 
Among the PI/r-regimens the most frequent combinations were LPV/r+ ZDV/3TC 
(1325/4698, 28·2%) and ATV/r+ TDF/FTC (535/4698, 11·4%) and among the NNRTI-
regimens were EFV+ TDF/FTC (495/4698, 10·5%) and NVP+ 3TC/ABC (288/4698, 6·1%) 
(SDC Table 3). Thirty women with a CD4 count >350cells/mm3 who started NVP in 
pregnancy were excluded from the analysis as NVP initiation is not recommended when 
CD4 count >250cells/mm3. 
The highest PTD rates (21·2% and 21·1% respectively) were observed in women with 
CD4 count ≤350 cells/mm3, namely, in those who did conceive on LPV/r+ TDF/FTC and in 
those who did not conceive on ART and received DRV/r+ TDF/FTC in pregnancy. 
Results from stratified analyses did not show any clear trend in PTD risk according to 
ART class and drug combination. Among women with CD4 count >350 cells/mm3, PTD 
risk was three-fold higher when conceiving on DRV/r+ TDF/FTC or LPV/r+ TDF/FTC than 
when conceiving on ATV/r+ TDF/FTC. However, in women with CD4 count ≤350 
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cells/mm3 PTD risk was higher in women conceiving on ATV/r+ TDF/FTC than with any 
other drug combinations. (Figure 3) 
Discussion 
In this national surveillance study, preterm births accounted for around 10% of all 
included singletons. An association between RTV-boosted PIs and PTD was observed but 
this was not consistent across all PIs. Among women who conceived on ART we found 
an increased risk of PTD in women on LPV/r compared with women who conceived on 
an NNRTI-based (mainly EFV and NVP) regimen even after taking into account other 
factors associated with PTD and irrespective of whether CD4 count was above or below 
350cells/mm3. The associations between other PI-based (mainly ATV/r and DRV/r) 
regimens and PTD risk were complex, with significant associations seen in some sub-
groups but not in others. There was no trend in PTD across TDF-containing regimens, 
and no clear pattern when considering the most common drug combinations. Overall, 
PTD risk was higher in women who conceived on ART, had low CD4 count and were 
older (>36 years), with VPTD risk also increased in women with a history of injecting 
drug use. 
Our findings on PTD associated with LPV/r are consistent with other studies, although 
there are differences. The PROMISE randomized clinical trial [10] reported significant 
higher PTD risk in the LPV/r+ TDF+FTC arm compared with the LPV/r+3TC/ZDV or 
mono ZDV+sdNVP arms although all participants initiated ART in pregnancy with CD4 
count >350 cells/mm3. Conversely, the main findings of a surveillance study in Botswana 
[21] suggested that PTD risk was higher in women conceiving on LPV/r+ ZDV/3TC than 
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in women conceiving on LPV/r +TDF/FTC, although the authors could not adjust or 
stratify analysis by CD4 count. When considering women with CD4>350 cells/mm3 
(Supplementary Online Content [21]) those on LPV/r+ TDF/FTC tended to have higher 
PTD risk than those on LPV/r+ ZDV/3TC (EFV+ TDF/FTC as the reference). It is 
therefore difficult to compare these results with our findings. A further study [22] that 
had randomised Ugandan women to LPV/r or EFV-based ART at 12-28 weeks gestation 
found no significant different in PTD risk between LPV/r- and EFV-based ART. In our 
study, the association between LPV/r and PTD was only seen among women on ART at 
conception, and not among those starting treatment in pregnancy. 
Overall, we found that women who conceived on ART were at higher risk of PTD than 
those starting ART in pregnancy. The size of our dataset and availability of CD4 data 
meant we could stratify women who conceived on ART by CD4 group, finding that PTD 
rate was much higher (13·7%) in women with CD4 ≤350 than in women with CD4 >350 
(8·8%). This is an important result as a recent systematic review and meta-analysis [4] 
that summarized findings from 11 studies showed an increased risk of PTD with pre-
conception initiation of ART but authors could not differentiate between women with low 
and high CD4 count because of lack of data. Similarly, a very recent study using data of 
HIV-infected women delivering in a hospital in Malawi between 2012 and 2015 [23], a 
period marking the implementation of Option B+, found that women conceiving on ART 
were at lower risk of delivering PTD compared to those starting ART in pregnancy. 
However, analyses were not adjusted for CD4 count (data not available) and the Option 
B+ regimen did not include PIs. 
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The association of PTD with ART is likely to be multi-factorial. Untreated HIV infection 
is associated with a Th1 to Th2 immunological shift, as is normal pregnancy. As ART 
reverses this „normal‟ shift in pregnant patients with HIV [24], it has been postulated that 
this might be associated with increased PTD risk. Biologically this effect, altering the 
balance of cytokines, might be expected to have most impact where ART was initiated 
during pregnancy. However, the data presented here and by others [5, 1, 25] point to a 
greater effect of ART on PTD risk if initiated prior to conception. 
Most consistent in the literature has been the association of PTD with PIs. A Canadian 
study [26] reported the OR of PTD with boosted PIs to be twice that of unboosted PI, 
raising the question of the direct impact of the booster as well as an indirect effect via 
higher drug concentrations. Data are lacking on the effect of full dose RTV (600mg bd) 
on PTD. However, a pattern emerges from our data of lower PTD with boosted ATV 
(100mg RTV daily) compared with LPV (100mg RTV bd) and darunavir (RTV 100mg 
daily or bd). In the PROMISE study [13] LPV/r dose was increased for the third trimester 
resulting in exposure to RTV 150mg twice daily. We excluded women on unboosted PIs 
from our analysis, as the small number precluded statistical comparison with other 
groups; the PTD rate in this group was 5·2%. PIs are associated with reduced levels of 
progesterone [9], possibly by reducing prolactin levels and increasing placental 
expression of the prolactin-regulated, progesterone-inactivating enzyme 20-α-
hydroxysteroid dehydrogenase (20α-HSD) [27] and a study of topical cervical 
progesterone in HIV has been proposed to explore whether this improves perinatal 
outcomes [11], but it is clear that more research is needed, including to understand the 
effect of PI exposure throughout pregnancy on progesterone levels. The PROMISE study 
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focused attention on the role of nucleosides/nucleotides; one interpretation of the 
PROMISE results is that TDF/FTC is associated, at least when administered with LPV/r, 
with increased PTD risk. In our study an increased PTD risk was seen when TDF/FTC 
were administered with LPV/r but not with ATV/r (possibly due to lower ATV/r 
concentrations with TDF) nor with NNRTIs, suggesting that TDF/FTC per se are not 
associated with PTD risk. An alternative hypothesis could be that ZDV-based therapies 
are associated with lower risk of PTD, supported by data from the PROMISE [13] and 
Mma Bana [7] studies (ABC/ZDV/3TC) and by data from the NSHPC on ZDV 
monotherapy and ZDV/3TC dual therapy [2]. In another clinical trial conducted in 
Uganda the backbone to both arms (EFV v LPV/r) was ZDV+3TC, with no significant 
difference in PTD observed (16·2% with LPV/r v 14.7% with EFV) [22]. Finally, 
restoration of immune function with treatment may unmask otherwise hidden risks for 
PTD. A resurgence in risk of pre-eclampsia has been reported in the cART era, whereas 
mothers on ZDV monotherapy had lower than expected rates [28]. This might be 
considered a form of immune reconstitution inflammatory syndrome (IRIS), and would 
not necessarily be class-specific, as such an effect would correlate with overall regimen 
efficacy. 
The size of the NSHPC dataset allowed us to stratify analyses by CD4 count and ART at 
conception to minimize bias in treatment indication, as well as to investigate PTD risk 
associated with the most commonly prescribed regimens in the UK between 2007 and 
2015. However, our study had some limitations. There was some systematic bias as we 
excluded a priori women exposed to ART for <28 days before delivery. In this group the 
PTD rate was extremely high (42/145, 29·0%) and the reasons behind this are likely to be 
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complex and deserve separate investigation. We could not adjust for maternal HIV 
disease stage prior to conception or nadir CD4 count (because data not collected by 
NSHPC) or other co-infections, which may increase the risk of PTD or determine ART 
regimen choice. Until recently, ART was prescribed outside of the context of pregnancy 
to women with immune deficiency and/or low CD4 count. Women starting treatment 
before conception in earlier years were more likely to have started because of HIV 
disease, and may therefore have risk factors for adverse pregnancy outcome not present 
in women first starting ART during pregnancy [15, 16]. This scenario (and thus residual 
confounding) may be particularly relevant to women who conceived on LPV/r (as LPV/r 
was more frequently prescribed in earlier years of the study) and DRV/r. DRV-based 
regimens were recommended second-line in UK guidelines between 2008 and 2012, 
implying higher prevalence of previous severe maternal HIV disease and/or virological 
failure. Pregnant women living with HIV in the UK/Ireland have risk factors for PTD in 
common with the general population, such as such as older maternal age and injecting 
drug use, or coming from communities at increased PTD risk, such as women originating 
in the Caribbean [29]. However, we were not able to adjust our analyses for other 
important PTD risk factors such previous PTD, maternal body mass index, smoking and 
socio-economic status because the NSHPC does not collect this information. 
Our data support a link between the initiation of LPV/r-based ART prior to pregnancy 
and subsequent PTD, which should be factored into treatment guidelines. Although rarely 
prescribed in the UK now, LPV/r-based regimens are still used by large numbers of 
pregnant women living with HIV in Eastern Europe [30, 31]. Our findings also show 
increased PTD risk among women on other specific regimens at conception with CD4 
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counts above 350 cells/mm3. This is of particular relevance given the rapid growth in the 
number of women with HIV conceiving on ART expected in lower and middle income 
settings with current guidelines to initiate ART at any CD4 cell count [32], and the 
implications of PTD for infant morbidity and mortality in such settings [33]. The public 
health approach to HIV treatment in lower and middle income settings precludes an 
individualized approach to ART according to women‟s childbearing potential/intent and 
PTD risk, and the safest regimens for all women therefore need to be identified and 
included in guidelines. 
Conclusions 
Our data support a link between the initiation of RTV-boosted/LPV-based ART pre-
conception and PTD in subsequent pregnancies. These, and other data associating the 
pre-conception choice of ART with pregnancy outcomes have implications for adult and 
not just pregnancy treatment guidelines given that increasing numbers of pregnancies 
worldwide are conceived on ART [34]. Although the benefits of ART for pregnant 
women living with HIV and their infants are clear, data on safety and pharmacokinetics 
in pregnancy are lacking, particularly for newer drugs and classes and continued 
monitoring of PTD risk is needed. 
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Table 1 Characteristics of all pregnancies by NNRTI‐, LPV/r‐ and other PI‐based regimens. 




PTD (<37 GW) 169(9.0) 
MPTD (36-34 GW) 98(5.2) 
PTD (<34 GW) 71(3.8) 
Year of Delivery 
2007-2009 466(24.7) 
 





2010-2012 704(37.3) 952(40.2) 637(35.1) 
2013-2015 719(38.1) 224(9.5) 841(46.3) 
Maternal age at delivery <0.001 
<28 years 305(16.2) 724(30.6) 430(23.7) 
28-32 years 415(22.0) 644(27.2) 455(25.1) 
33-36 years 575(30.4) 568(24.0) 475(26.2) 
>36 years 594(31.5) 432(18.2) 456(25.1) 
Years since HIV diagnosis 6.0(3.4-8.5) 2.6(0.5-5.6) 5.2(2.0-8.4) <0.001b 
Regions of origin <0.001 
WEWC+EE 263(13.9) 495(20.9) 389(21.4) 
East Africa 934(49.4) 1003(42.4) 681(37.5) 
West Africa 309(16.4) 369(15.6) 357(19.7) 
Mid/South Africa 239(12.7) 305(12.9) 237(13.1) 
Caribbean 44(2.3) 45(1.9) 41(2.3) 
Other 100(5.3) 151(6.4) 111(6.1) 
2368(39.0) 1816(29.9) P‐valuea 
N (%) N (%) 
 



















Baseline CD4 (cells/mm3) (n=4377) 0.016 
CD4>350 1047(71.1) 1225(65.9) 1000(69.3) 
CD4~350 426(28.9) 635(34.1) 44(30.8) 
Median(IQR) 456(325-610) 430(303-582) 441 (317-605) 0.004 b 
ART at conception 1577(83.5) 565(23.9) 948(52.2) <0.001 
Mode of delivery <0.001 
Vaginal 765(41.0) 930(39.5) 779(43.6) 
Emergency CS 500(26.8) 555(23.6) 462(25.9) 
Elective CS 601(32.2) 868(36.9) 544(30.5) 
Small for gestational age 338 (19.2) 494 (21.6) 331 (19.9) 0.15 
Birthweight (g) - 3090 3020 3062 0.19 b 
median(IQR) (2700-3430) (2700-3380) (2620-3440) 
PTD= pre-term, MPTD= moderate pre-term, VPTD= very pre-term, WEWC + WW= Western Europe 
(UK/Ireland excluded) and Westernised countries + Eastern Europe, IDU= intraveneous drug use, 
CS= Caesearian Section. 
a b 
p-value for Chi-square test unless stated; p-value for Kruskal Wallis test. 
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Table 2 Associations of PTD with NNRTI‐, LPV/r‐ and other PI‐based regimens 
 N 
 6073 
ART class in pregnancy  
NNRTI+2NRTI 1889 
LPV/r+2NRTI 2368 
Other PI/r+2NRTI 1816 
 
9.0 1.00 1.00 
12.0 1.39 (1.13,1.70) 1.56 (1.19,2.04) 
9.7 1.09 (0.88,1.36) 1.10 (0.84,1.45) 
Delivery year (per 1 year increase)b 0.95 (0.92, 0.98) 0.96 (0.92,1.01) 
11.6 - - 
10.2 - - 
9.3 - - 
Maternal age at delivery 
<28years 1459 9.9 1.00 1.00 
28-32years 1514 10.9 1.12 (0.88,1.41) 1.23 (0.92,1.63) 
33-36years 1618 9.3 0.93 (0.73,1.19) 1.12 (0.84,1.50) 
>36years 1482 11.5 1.18 (0.94,1.50) 1.41 (1.05, 1.89) 
Maternal origin 
WEWC+EE 1147 12.1 1.40 (1.03,1.90) 1.34 (0.94, 1.93) 
East Africa 2618 10.1 1.14 (0.87,1.51) 1.08 (0.79,1.49) 
West Africa 1035 9.7 1.09 (0.79,1.50) 1.08 (0.75, 1.57) 
Mid/Southern Africa 781 9.0 1.00 1.00 
Caribbean 130 14.6 1.74 (1.01,3.00) 1.83 (0.98, 3.40) 
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1.00 1.00 
0.93 (0.78,1.11) 1.00 (0.80, 1.24) 
1.00 1.00 
1.81 (1.08,3.03) 1.58 (0.84, 2.96) 
1.00 1.00 
0.96 (0.82,1.14) 1.27 (1.01,1.61) 
1.00 1.00 
≤350 cells/mm3 1505 11.5 1.24 (1.02,1.51) 1.28 (1.04,1.58) 
Primiparous 1784 10.8 
Multiparous 4161 10.1 
History of IDU   
No 5968 10.2 
Yes 105 17.1 
ART at conception   
No 2983 10.5 
Yes 3090 10.2 
c 
First antenatal CD4 count 
  
>350 cells/mm3 3272 9.5 
 
